Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc., announced new findings that show MHC-II protein expression is a more reliable predictor of response to pembrolizumab (Keytruda®) than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback